# Roflumilast Versus Methotrexate in Psoriasis

> **NCT05684744** · PHASE2,PHASE3 · COMPLETED · sponsor: **Cairo University** · enrollment: 30 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Roflumilast
- **DRUG:** Methotrexate

## Key facts

- **NCT ID:** NCT05684744
- **Lead sponsor:** Cairo University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-09
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-05-14
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2023-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05684744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05684744, "Roflumilast Versus Methotrexate in Psoriasis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05684744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*